Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Levofloxacin [USAN:INN:JAN]
RN: 100986-85-4
UNII: RIX4E89Y14
InChIKey: GSDSWSVVBLHKDQ-JTQLQIEISA-N

Note

  • A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION./Ofloxacin/

Molecular Formula

  • C18-H20-F-N3-O4

Molecular Weight

  • 361.371
 

Classification Codes

  • Anti-Infective Agents, Urinary
  • Antiviral (COVID-19)
  • Drug / Therapeutic Agent
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Levofloxacin
  • Levofloxacin [USAN:INN:JAN]

Synonyms

  • (-)-Ofloxacin
  • (S)-(-)-Ofloxacin
  • (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
  • (S)-Ofloxacin
  • CCRIS 4074
  • Cravit
  • DR3355
  • Elequine
  • HR 355
  • HSDB 8028
  • Iquix
  • Levaquin
  • Levaquin in dextrose 5% in plastic container
  • Levofloxacin
  • Levofloxacine
  • Levofloxacine [INN-French]
  • Levofloxacino
  • Levofloxacino [INN-Spanish]
  • Levofloxacinum
  • Levofloxacinum [INN-Latin]
  • Loxof
  • MP 376
  • MP-376
  • NSC 758709
  • Ofloxacin S-(-)-form
  • Oftaquix
  • Quixin
  • RWJ 25213-097
  • Tavanic
  • Unibiotic
  • UNII-RIX4E89Y14
  • Venaxan

Systematic Names

  • (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
  • 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-
  • Levofloxacin

Registry Numbers

CAS Registry Number

  • 100986-85-4

FDA UNII

  • RIX4E89Y14

System Generated Number

  • 0100986854

Structure Descriptors

InChI

InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

InChIKey

GSDSWSVVBLHKDQ-JTQLQIEISA-N

Smiles

C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(=O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
monkey LD50 oral > 250mg/kg (250mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION		 Arzneimittel-Forschung. Drug Research. Vol. 42, Pg. 365, 1992.
mouse LD50 oral 1803mg/kg (1803mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Arzneimittel-Forschung. Drug Research. Vol. 42, Pg. 365, 1992.
rat LD50 oral 1478mg/kg (1478mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION		 Arzneimittel-Forschung. Drug Research. Vol. 42, Pg. 365, 1992.
women TDLo oral 122mg/kg/10D- (122mg/kg) MUSCULOSKELETAL: OTHER CHANGES Annals of Pharmacotherpy. Vol. 33, Pg. 792, 1999.